Saltar al contenido
Merck

B8810

BAY 41-2272

≥97% (HPLC)

Sinónimos:

3-(4-Amino-5-cyclopropylpyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C20H17FN6
Número CAS:
256376-24-6
Peso molecular:
360.39
NACRES:
NA.77
PubChem Substance ID:
24892096
UNSPSC Code:
12352200
MDL number:
MFCD06411391

Nombre del producto

BAY 41-2272, ≥97% (HPLC)

InChI key

ATOAHNRJAXSBOR-UHFFFAOYSA-N

SMILES string

Nc1nc(ncc1C2CC2)-c3nn(Cc4ccccc4F)c5ncccc35

InChI

1S/C20H17FN6/c21-16-6-2-1-4-13(16)11-27-20-14(5-3-9-23-20)17(26-27)19-24-10-15(12-7-8-12)18(22)25-19/h1-6,9-10,12H,7-8,11H2,(H2,22,24,25)

assay

≥97% (HPLC)

form

powder

color

white to light brown

mp

210.5-211.4 °C

solubility

DMSO: 5 mg/mL, clear (warmed)

originator

Bayer

storage temp.

2-8°C

Quality Level

100

Application

BAY 41-2272 has been used for the stimulation of guanylate cyclase in heart and neurons.

Biochem/physiol Actions

BAY 41-2272 is an activator of soluble guanylate cyclase at a novel, NO-independent regulatory site. BAY 41-2272 is the first product that stimulates sGC through a non-NO mechanism. BAY 41-2272 inhibits platelet aggregation and induces vasorelaxation without nitrate tolerance.
BAY 41-2272 is an activator of soluble guanylate cyclase; stimulates sGC through a non-NO mechanism; inhibits platelet aggregation, and induces vasorelaxation without nitrate tolerance.

Features and Benefits

This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000489347
0000489346
0000489346
0000489347
0000481255

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Traci R Tuttle et al.
Cancer letters, 389, 33-40 (2016-12-28)
Head and neck squamous cell carcinoma (HNSCC) is an aggressive and often fatal disease. Cisplatin is the most common chemotherapeutic drug in the treatment of HNSCC, but intrinsic and acquired resistance are frequent, and severe side effects occur at high
Benjamin Vandendriessche et al.
PloS one, 8(8), e72155-e72155 (2013-09-10)
Sepsis and septic shock are associated with high mortality rates and the majority of sepsis patients die due to complications of multiple organ failure (MOF). The cyclic GMP (cGMP) producing enzyme soluble guanylate cyclase (sGC) is crucially involved in the
Jennifer C Irvine et al.
PloS one, 7(11), e44481-e44481 (2012-11-13)
Although evidence now suggests cGMP is a negative regulator of cardiac hypertrophy, the direct consequences of the soluble guanylyl cyclase (sGC) activator BAY 58-2667 on cardiac remodeling, independent of changes in hemodynamic load, has not been investigated. In the present
Female sexual behavior in mice is controlled by kisspeptin neurons
Hellier V, et al.
Nature Communications, 9(1), 400-400 (2018)
Katalin Bartus et al.
PloS one, 8(2), e57292-e57292 (2013-03-02)
In the hippocampus, as in many other CNS areas, nitric oxide (NO) participates in synaptic plasticity, manifested as changes in pre- and/or postsynaptic function. While it is known that these changes are brought about by cGMP following activation of guanylyl
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico